Company: Bristol-Myers Squibb Co

Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.    Read More

A crush of earnings news in the coming week will compete head on with new data on the health of the U.S. economy and worries about Europe’s debt crisis.   Read More

Human Genome Sciences is one of the reasons the NYSE Arca Biotech Index is having its best day since December 2010.    Read More

In 2011, Mylan’s longtime chief executive Robert Coury, who gave up the post at the end of the year to become executive chairman (he’s also chairman of the board) earned cash compensation of $7.4 million.    Read More

Why Amylin Pharmaceuticals shareholders should demand transparency and a public explanation of recent takeover talk.    Read More

CNBC's quarterly list of S&P 500 stocks with the potential to underperform did just that — they rose by only 5.6 percent since Jan. 10, compared with the 8.8 percent gain for the index.    Read More

Information technology and healthcare are two sectors where investors can find value, Peter Garnry, equity strategist at Saxo Bank told CNBC.   Read More

Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.   Read More

Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.    Read More

Since the beginning of the year, buying the losers and selling the winners seems to have paid off.     Read More